[1]张亦涵,徐浣白.雌激素及其信号通路与甲状腺乳头状癌关系的研究进展[J].国际内分泌代谢杂志,2023,43(03):225-228.[doi:10.3760/cma.j.cn121383-20220501-05001]
 Zhang Yihan,Xu Huanbai..Clinical features and role of estrogen/estrogen receptor in papillary thyroid carcinoma in women[J].International Journal of Endocrinology and Metabolism,2023,43(03):225-228.[doi:10.3760/cma.j.cn121383-20220501-05001]
点击复制

雌激素及其信号通路与甲状腺乳头状癌关系的研究进展()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年03期
页码:
225-228
栏目:
综述
出版日期:
2023-05-20

文章信息/Info

Title:
Clinical features and role of estrogen/estrogen receptor in papillary thyroid carcinoma in women
作者:
张亦涵徐浣白
上海交通大学医学院附属第一人民医院内分泌代谢科,上海 200080
Author(s):
Zhang Yihan Xu Huanbai.
Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
关键词:
女性 甲状腺乳头状癌 雌激素 雌激素受体
Keywords:
Woman Papillary thyroid carcinoma Estrogen Estrogen receptor
DOI:
10.3760/cma.j.cn121383-20220501-05001
摘要:
甲状腺乳头状癌(PTC)在女性中有较高的发病率,且女性PTC发病率受年龄等因素影响,这提示雌激素/雌激素受体(ERs)在PTC中发挥独特作用,多数研究证明ERα表达与PTC成正相关性,而ERβ与PTC发生呈负相关。且在PTC进程中雌激素可对ERs表达及肿瘤微环境造成影响。调控雌激素/ERs在PTC中的表达已经成为雌激素相关肿瘤治疗中重要的一部分。分析PTC女性发病的特点,探索不同ERs在甲状腺肿瘤中的作用,可为治疗疾病提供新的思路。
Abstract:
Papillary thyroid carcinoma(PTC)has a high incidence rate in women, and is affected by age, menopause and other factors. Estrogen receptors(ERs)play a unique role in PTC. In this paper, ERs is discussed more specifically. Most studies have demonstrated a positive correlation between ERα expression with PTC. Most studies have shown that ERβ is negatively correlated with PTC. Estrogen can affect ERs expression and tumor microenvironment during PTC process. Regulation of estrogen/ERs expression in PTC has become an important part in the treatment of estrogen-associated tumors. To analyze the characteristics of female incidence in PTC and explore the role of different ERs in thyroid tumors may provide new ideas for the treatment of the disease.

参考文献/References:

[1] Cabanillas ME,McFadden DG,Durante C.Thyroid cancer[J].Lancet,2016,388(10061):2783-2795.DOI:10.1016/S0140-6736(16)30172-6.
[2] Lamartina L,Grani G,Arvat E,et al.8th edition of the AJCC/TNM staging system of thyroid cancer:what to expect(ITCO#2)[J].Endocr Relat Cancer,2018,25(3):L7-L11.DOI:10.1530/ERC-17-0453.
[3] Baloch ZW,Asa SL,Barletta JA,et al.Overview of the 2022 WHO classification of thyroid neoplasms[J].Endocr Pathol,2022,33(1):27-63.DOI:10.1007/s12022-022-09707-3.
[4] Nath MC,Erickson LA.Aggressive variants of papillary thyroid carcinoma:hobnail,tall cell,columnar,and solid[J].Adv Anat Pathol,2018,25(3):172-179. DOI: 10.1097/PAP.0000000000000184.
[5] Cheng F,Xiao J,Shao C,et al. Burden of thyroid cancer from 1990 to 2019 and projections of incidence and mortality until 2039 in China:findings from global burden of disease study[J].Front Endocrinol(Lausanne),2021,12:738213.DOI:10.3389/fendo.2021.738213.
[6] Douglas EH,Rhoads A,Thomas A,et al.Incidence and survival in reproductive-aged women with differentiated thyroid cancer:United States SEER 18 2000-2016[J].Thyroid,2020,30(12):1781-1791.DOI:10.1089/thy.2020.0152.
[7] Ganly I,Ibrahimpasic T,Rivera M,et al.Prognostic implications of papillary thyroid carcinoma with tall-cell features[J].Thyroid,2014,24(4):662-670.DOI:10.1089/thy.2013.0503.
[8] Kwon H,Chang Y,Cho A,et al.Metabolic obesity phenotypes and thyroid cancer risk:a cohort study[J].Thyroid,2019,29(3):349-358.DOI:10.1089/thy.2018.0327.
[9] Fuentes N,Silveyra P.Estrogen receptor signaling mechanisms[J].Adv Protein Chem Struct Biol,2019,116:135-170.DOI:10.1016/bs.apcsb.2019.01.001.
[10] Chou CK,Chi SY,Hung YY,et al.Decreased expression of estrogen receptors is associated with tumorigenesis in papillary thyroid carcinoma[J].Int J Mol Sci,2022,23(3):1015.DOI:10.3390/ijms23031015.
[11] Meng D,Li Z,Ma X,et al.MicroRNA-1280 modulates cell growth and invasion of thyroid carcinoma through targeting estrogen receptor α[J].Cell Mol Biol(Noisy-le-grand),2016,62(3):1-6.
[12] Zhou H, Xie X, Chen Y,et al.Chaperone-mediated autophagy governs progression of papillary thyroid carcinoma via PPARgamma-SDF1/CXCR4 signaling[J].J Clin Endocrinol Metab,2020,105(10):dgaa366.DOI:10.1210/clinem/dgaa366.
[13] Xue L,Yan H,Chen Y,et al.EZH2 upregulation by ERa induces proliferation and migration of papillary thyroid carcinoma[J].BMC Cancer,2019,19(1):1094.DOI:10.1186/s12885-019-6306-9.
[14] Mo XM,Li L,Zhu P,et al.Up-regulation of Hsp27 by ERa/Sp1 facilitates proliferation and confers resistance to apoptosis in human papillary thyroid cancer cells[J].Mol Cell Endocrinol,2016,431:71-87.DOI:10.1016/j.mce.2016.05.010.
[15] Dong WW,Li J,Li J,et al.Reduced expression of oestrogen receptor-β is associated with tumour invasion and metastasis in oestrogen receptor-α-negative human papillary thyroid carcinoma[J].Int J Exp Pathol,2018,99(1):15-21.DOI:10.1111/iep.12266.
[16] Qiu YB,Liao LY,Jiang R,et al.PES1 promotes the occurrence and development of papillary thyroid cancer by upregulating the ERα/ERβ protein ratio[J].Sci Rep,2019,9(1):1032.DOI:10.1038/s41598-018-37648-7.
[17] Liu C,Wu HT,Zhu N,et al.Steroid receptor RNA activator:biologic function and role in disease[J].Clin Chim Acta,2016,459:137-146.DOI:10.1016/j.cca.2016.06.004.
[18] Li M,Chai HF,Peng F,et al.Estrogen receptor β upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma[J].Cell Death Dis,2018,9(11):1120.DOI:10.1038/s41419-018-1077-9.
[19] Manole D,Schildknecht B,Gosnell B,et al.Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms[J].J Clin Endocrinol Metab,2001,86(3):1072-1077.DOI:10.1210/jcem.86.3.7283.
[20] Faria CC,Peixoto MS,Carvalho DP,et al.The emerging role of estrogens in thyroid redox homeostasis and carcinogenesis[J].Oxid Med Cell Longev,2019,2019:2514312.DOI:10.1155/2019/2514312.
[21] Chen D,Tan Y,Li Z,et al.Organoid cultures derived from patients with papillary thyroid cancer[J].J Clin Endocrinol Metab,2021,106(5):1410-1426.DOI:10.1210/clinem/dgab020.
[22] Somjen D,Grafi-Cohen M,Posner GH,et al.Vitamin D less-calcemic analog modulates the expression of estrogen receptors, vitamin D receptor and 1α-hydroxylase 25-hydroxy vitamin D in human thyroid cancer cell lines[J].J Steroid Biochem Mol Biol,2013,136:80-82.DOI:10.1016/j.jsbmb.2012.09.015.
[23] Yao R,Chiu CG,Strugnell SS,et al.Gender differences in thyroid cancer:a critical review[J].Expert Rev Endocrinol Metab,2011.6(2):215-243.DOI:10.1586/eem.11.9.
[24] Liu J,Xu T,Ma L,et al.Signal pathway of estrogen and estrogen receptor in the development of thyroid cancer[J].Front Oncol,2021,11:593479.DOI:10.3389/fonc.2021.593479.
[25] Hannibal CG,Jensen A,Sharif H,et al.Risk of thyroid cancer after exposure to fertility drugs:results from a large Danish cohort study[J].Hum Reprod,2008,23(2):451-456.DOI:10.1093/humrep/dem381.
[26] Moleti M,Sturniolo G,Di Mauro M,et al.Female reproductive factors and differentiated thyroid cancer[J].Front Endocrinol(Lausanne),2017,8:111.DOI:10.3389/fendo.2017.00111.

相似文献/References:

[1]李潍 陈晓铭 武革.长链非编码RNA在甲状腺乳头状癌中的作用[J].国际内分泌代谢杂志,2015,(06):413.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.014]
 Li Wei,Chen Xiaoming,Wu Ge.Roles of long non-coding RNA in papillary thyroid carcinoma[J].International Journal of Endocrinology and Metabolism,2015,(03):413.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.014]
[2]程燕,何启胜.血清miR-451a、 miR-25-3p、GAS8-AS1联合 检测用于早期甲状腺乳头状癌的诊断[J].国际内分泌代谢杂志,2020,40(05):300.[doi:10.3760/cma.j.cn121383-20200306-03016]
 Cheng Yan,He Qisheng. Department of Endocrinology,Chizhou People's Hospital,et al.Diagnosis of early papillary thyroid carcinoma by combined detection of serum miR-451a, miR-25-3p, and GAS8-AS1[J].International Journal of Endocrinology and Metabolism,2020,40(03):300.[doi:10.3760/cma.j.cn121383-20200306-03016]
[3]黄丽君.环状RNA的功能及其在甲状腺乳头状癌中的作用[J].国际内分泌代谢杂志,2022,42(01):58.[doi:10.3760/cma.j.cn121383-20200927-09052]
 Huang Lijun..Function of circRNAs and its role in thyroid papillary carcinoma[J].International Journal of Endocrinology and Metabolism,2022,42(03):58.[doi:10.3760/cma.j.cn121383-20200927-09052]

备注/Memo

备注/Memo:
通信作者:徐浣白,Email: huanbaixu@126.com
更新日期/Last Update: 2023-05-20